MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1056/nejmoa1911326

Медицинская библиотека · The New England journal of medicine · 2020

Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.

Locatelli Franco, Jordan Michael B, Allen Carl, Cesaro Simone, Rizzari Carmelo, Rao Anupama, Degar Barbara, Garrington Timothy P, Sevilla Julian, Putti Maria-Caterina, Fagioli Franca, Ahlmann Martina, Dapena Diaz Jose-Luis, Henry Michael, De Benedetti Fabrizio, Grom Alexei, Lapeyre Genevieve, Jacqmin Philippe, Ballabio Maria, de Min Cristina

Клиническое исследование II фазыКлиническое исследование III фазыСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Primary hemophagocytic lymphohistiocytosis is a rare syndrome characterized by immune dysregulation and hyperinflammation. It typically manifests in infancy and is associated with high mortality.

METHODS

We investigated the efficacy and safety of emapalumab (a human anti-interferon-γ antibody), administered with dexamethasone, in an open-label, single-group, phase 2-3 study involving patients who had received conventional therapy before enrollment (previously treated patients) and previously untreated patients who were 18 years of age or younger and had primary hemophagocytic lymphohistiocytosis. The patients could enter a long-term follow-up study until 1 year after allogeneic hematopoietic stem-cell transplantation or until 1 year after the last dose of emapalumab, if transplantation was not performed. The planned 8-week treatment period could be shortened or extended if needed according to the timing of transplantation. The primary efficacy end point was the overall response, which was assessed in the previously treated patients according to objective clinical and laboratory criteria.

RESULTS

At the cutoff date of July 20, 2017, a total of 34 patients (27 previously treated patients and 7 previously untreated patients) had received emapalumab; 26 patients completed the study. A total of 63% of the previously treated patients and 65% of the patients who received an emapalumab infusion had a response; these percentages were significantly higher than the prespecified null hypothesis of 40% (P = 0.02 and P = 0.005, respectively). In the previously treated group, 70% of the patients were able to proceed to transplantation, as were 65% of the patients who received emapalumab. At the last observation, 74% of the previously treated patients and 71% of the patients who received emapalumab were alive. Emapalumab was not associated with any organ toxicity. Severe infections developed in 10 patients during emapalumab treatment. Emapalumab was discontinued in 1 patient because of disseminated histoplasmosis.

CONCLUSIONS

Emapalumab was an efficacious targeted therapy for patients with primary hemophagocytic lymphohistiocytosis. (Funded by NovImmune and the European Commission; NI-0501-04 and NI-0501-05 ClinicalTrials.gov numbers, NCT01818492 and NCT02069899.).

Для цитирования: Locatelli Franco, Jordan Michael B, Allen Carl, Cesaro Simone, Rizzari Carmelo, Rao Anupama, Degar Barbara, Garrington Timothy P, Sevilla Julian, Putti Maria-Caterina, Fagioli Franca, Ahlmann Martina, Dapena Diaz Jose-Luis, Henry Michael, De Benedetti Fabrizio, Grom Alexei, Lapeyre Genevieve, Jacqmin Philippe, Ballabio Maria, de Min Cristina. Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.. The New England journal of medicine. 2020. DOI: 10.1056/nejmoa1911326.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.